Senores Pharmaceuticals Limited — Investor Meet, 27-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Senores Pharma reported robust Q3FY26: Income INR175Cr (+64% YoY), EBITDA INR54Cr (+86% YoY), PAT INR32Cr (+85% YoY). 9MFY26 results track ahead of annual guidance. Growth driven by regulated markets (+60% YoY), emerging markets (+48% YoY), and India branded generics (+6x YoY).

Strategic update: 75% Apnar Pharma acquisition complete, expanding US, UK, Canada manufacturing & market access. Portfolio now 46 approved ANDAs; 28 approved for launch in 6-8 quarters. Regulated market gross margins around 40%; emerging market EBITDA margins improving. Management confident in sustained growth from pipeline and strategic initiatives. FY27 outlook projects minimum 25%+ top-line growth.